Immunopurification of Human Coagulation Factor IX Using Monoclonal Antibodies

Summary

This study examines the suitability of four recently characterised monoclonal antibodies (MAbs) for the immunoaffinity purification of human coagulation factor IX (FIX) from plasma concentrates. Initial studies using ¹²⁵I-FIX indicated that appreciable amounts of bound FIX could be eluted from immobilised MAbs with 0.2 M glycine, 50% ethanediol pH 10 (buffer N). Further studies with FIX concentrates showed that buffer N eluted FIX without compromising the activity of the zymogen. Although FIX was eluted from all four MAbs with this buffer, the best yield (82%) was obtained with MAb ESN-3. ESN-3 bound 40 to 60 iu FIX per mg MAb when immobilised on Sepharose 4B. After washing, column elution with buffer N yielded FIX at 100-200 iu/mg. The purity of the product was confirmed by sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and by Western blotting. The product contained no detectable mouse IgG (<3%) and <1% FII, X, or protein C.

Keywords

Factor IX - Monoclonal antibodies - Immunopurification

• References

• 1 Smith JK, Bidwell E. Therapeutic materials used in the treatment of coagulation defects. Clinics in Haematology 1979; 8: 183-206
• 2 Pepper DS, Prowse CV. Chromatography of human prothrombin complex on dextran sulphate agarose. Thromb Res 1977; 11: 687-692
• 3 Goodall AH, Kemble G, O’Brien DP, Rawlings E, Rotblat F, Russeli GC, Janossy G, Tuddenham EG D. Preparation of factor IX deficient human plasma by immunoaffinity chromatography using a monoclonal antibody. Blood 1982; 59: 664-670
• 4 Menache D, Behre HE, Orthner CL, Nunez H, Anderson HD, Triantaphyllopoulos DC, Kosow DP. Coagulation FIX concentrate: method of preparation and assessment of potential in vivo throm-bogenicity in animal models. Blood 1984; 64: 1220-1227
• 5 Aronson DL, Thomas DP. Experimental studies on venous thrombosis: effect of coagulants, procoagulants and vessel contusion. Thromb Haemostas 1985; 54: 866-870
• 6 Liebman HA, Limentani SA, Furie BC, Furie B. Immunoaffinity purification of factor IX (Christmas factor) by using conformation specific antibodies directed against the factor IX-metal complex. Proc Natl Acad Sci USA 1985; 82: 3879-3883
• 7 Anson DS, Austen DE G, Brownlee GG. Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells. Nature 1985; 315: 683-685
• 8 Smith KJ. Monoclonal antibodies to factor IX define a high-frequency polymorphism by immunoassays. Am J Hum Genet 1985; 37: 668-679
• 9 Bessos H, Micklem LR, McCann M, James K, McClelland DB L, Prowse CV. The characterization of a panel of monoclonal antibodies to human coagulation factor IX. Thromb Res 1985; 40: 863-867
• 10 Kohn J, Wilchek M. A new approach (cyanotransfer) for cyanogen bromide activation of sepharose at neutral pH, which yields activated resins free of interfering nitrogen derivatives. Biochem Biophys Res Comm 1982; 107: 878-884
• 11 Foster PR, Patterson MR, Johnson AJ, Middleton SM. Throm-bogenicity of FIX concentrates and polyethylene glycol processing. Vox Sang 1980; 17: 273-279
• 12 DiScipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, FIX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 1977; 16: 698-706
• 13 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
• 14 Jobin F, Esnouf MP. Coagulant activity of tiger snake (Notechis scutatus scutatus) venom. Nature 1966; 211: 873-875
• 15 Einarsson M, Brandt J, Kaplan L. Large scale purification of human tissue type plasminogen activator using monoclonal antibodies. Bioch Bioph Acta 1985; 830: 1-10
• 16 Prowse CV. Monoclonal antibodies and the haemostasis laboratory: current position. Vox Sang 1986; 50: 65-70
• 17 Katzmann JA, Nesheim ME, Hibbard LS, Mann KG. Isolation of functional human coagulation factor V by using a hybridoma antibody. Proc Natl Acad Sci USA 1981; 78: 162-166
• 18 Niday E, Brown C, Rowe W. Immunoaffinity isolation of human coagulation factor VII using monoclonal antibodies. Hybridoma 1984 3. 77A (Abstr.)
• 19 Miletich JP, Leykam JF, Broze Jr GJ. Detection of single chain protein C in human plasma. Blood (Suppl. 01) 1983; 62: 306a
• 0 Truett MA, Blacher R, Burke RL, Caput D, Chu C, Dina D, Hartog K, Kuo CH, Masiarz FR, Merryweather JP, Najarian R, Pachl C, Potter SJ, Puma J, Quiroga M, Rail LB, Randdolph A, Urdea MS, Valenzuela P, Dahl HH, Favalaro J, Hansen J, Nordfang O, Ezban M. Characterisation of the polypeptide composition of human factor VIII :C and the nucleotide sequence and expression of the human kidney CDNA. DNA 1985; 4: 333-349
• 21 Zimmerman TS. Fulcher. US Patent No. 4, 361, 509 1982
• 22 Hornsey V, Pepper DS, Prowse CV. Immunopurification of factor VIII complex on monoclonal antibodies to Von Willebrand factor. In preparation
• 23 Church WR, Mann KC. A simple purification of human factor X using a high affinity monoclonal antibody immunoadsorbant. Thromb Res 1985; 38: 417-424
• 24 Small EJ, Katzmann JA, Tracy RP, Ratnoff OD, Goldsmith Jr GH, Everson B. A monoclonal antibody that inhibits activation of human Hageman factor (factor XII). Blood 1985; 65: 202-210
• 25 Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zenthen J, Dano K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 1982; 24: 6410-6415
• 26 Schleef RR, Sinha M, Loskutoff DJ. Characterisation of two monoclonal antibodies against human tissue type plasminogen activators. Thromb Haemostas 1985; 53: 170-175
• 27 Astedt B, Lecander I, Brodin J, Lundbald A, Low K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemostas 1985; 53: 122-125
• 28 Fornstedt N. Affinity chromatographic studies on antigen antibody dissociation. FEBS 1984; 177: 195-199